Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

已完结 10 由小花花发布于 2026/3/6 14:11:57

DOI:10.1056/nejmoa2514752
作者：Shaji Kumar,María-Victoria Mateos,Jing Christine Ye,Shebli Atrash,Hila Magen,Hang Quach,Michael P Chu,Suzanne Trudel,Joshua Richter,Paula Rodríguez-Otero,Hun Chuah,Moshe Gatt,Eva Medvedova,Shahzad R
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1

应助信息

1天前

tao33

6021b70c192411f1af4b34735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/3/6 14:11:58 未找到该文献，机器人已退出，请等待人工下载

2026/3/6 14:11:58 Book学术AI机器人收到请求，开始寻找文献

2026/3/6 14:11:58 已向机器人发送请求

1天前

小花花发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierThermodynamic and emission analysis of CH4/H2/NH3 ternary fuel applied in gas turbine system under oxygen-rich atmosphere